Drug Profile
Research programme: antiviral therapeutics - F-star Therapeutics
Alternative Names: Broad-spectrum antiviral - F-star Therapeutics; RSV therapeutic - F-star Therapeutics; SB 9400; SB 9941; SB 9946Latest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator BioHEP Technologies
- Developer F-star Therapeutics
- Class Antivirals; Nucleic acids; Small molecules
- Mechanism of Action Immunomodulators; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections; Viral infections
Most Recent Events
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 20 Nov 2020 Spring Bank Pharmaceuticals has merged with F-star to form F-star Therapeutics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (PO)